Response to pneumococcal vaccine in systemic lupus erythematosus;Vacunación antineumococo en pacientes con lupus eritematoso sistémico

Medicina

Volumn 63, Issue 5, 2003, Pages 388-392

  Pisoni, Cecilia ^a   Sarano, Judith ^a   Benchetrit, Guillermo ^a   Rodríguez, Dolores ^a   Suárez, Lorena ^a   Perrota, Carla ^a   Manni, Jorge ^a  

^a INSTITUTO DE INVESTIGACIONES MÉDICAS ALFREDO LANARI   (Argentina)

Author keywords

Pneumococcal antibodies; Systemic lupus erythematosus; Vaccine

Indexed keywords

AUTOANTIBODY; CHLOROQUINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; MEPREDNISONE; PNEUMOCOCCUS VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DYSPHONIA; ERYTHEMA; FEMALE; FEVER; HUMAN; IMMUNOGENICITY; INFECTION RESISTANCE; INJECTION PAIN; INOCULATION; PRURITUS; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC LUPUS ERYTHEMATOSUS; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; AUTOANTIBODIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE;

EID: 0242539824     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5 year period. A multicenter prospective study of 1000 patients. European working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999; 78:167-75.
2. Elkayam O, Paran D, Caspi D, et al. Inmunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. CID 2002; 34:147-53.
3. Plouffe JF, Breiman RF, Facklam RR, Franklin County Pneumonia Study Group. Bacteremia with Streptococcus pneumoniae in adults, implications for therapy and prevention. JAMA 1996; 275: 194-8.
4. Poland GA. The prevention of pneumococcal disease by vaccines: promises and challenges. Infect Dis Clin N Am 2001; 15: 97-122.
5. Burman LA, Norrby R, Trollfors B. Invasive pneumococcal infections: incidence, predisposing factors and prognosis. Rev Infect Dis 1985; 7: 133-42.
6. Whitney CG, Schaffner W, Butler JC. Rethinking recommendations for use of pneumococcal vaccines in adults. CID 2001; 33: 662-75.
7. Jarret MP, Schiffman G, Barland P, Grayzel A. Impaired response to pneumococcal vaccine in systemic lupus erythematosus. Arthritis and Rheum 1980; 23: 1287-93.
8. Vacuna Antineumocóccica en: Ministerio de Salud y Acción Social, Secretaría de programas de Salud, Dirección de Epidemiología, Departamento de Inmunizaciones: Normas Nacionales de Vacunación, III Actualización, Noviembre 1997; 51-3.
9. Battafarano D, Battafarano N, Larsen L, et al. Antigen-Specific antibody responses in lupus patients following immunization. Arthritis and Rheum 1998; 41: 1828-34.
10. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE: Derivation of the SLEDAI: a disease activity index (SLEDAI) for lupus patients. Arthritis and Rheum 1992; 35: 630-40.
11. Musher DM, Luchi M, Watson DA, Hamilton R, Baughn RE. Pneumoccocal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non type specific cell wall polysaccharide. J Infect Dis 1990; 161: 728-35.
12. Avery RK. Vaccination of the adult rheumatology patient for prevention of infection in ACR medical aspects of rheumatic diseases. Lecture 2002, October 29, New Orleans, Louisiana. USA.
13. Nichol KL, Baken L, Vuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Inter Med 1999; 159: 2437-42.
14. Blumberg EA, Brozena SC, Stutman P, Wood D, Phan HM, Musher DM. Immunogenicity of Pneumococcal Vaccine in Heart Transplant Recipients. CID 2001; 32: 307-10.
15. Shapiro ED, Clemens JD. A controlled of the protective efficacy of pneumococcal vaccine for patients at high risk of serius infections. Ann Intern Med 1984; 101: 325-30.
16. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. The Adult and Adolescent Spectrum of HIV Disease Project. Pneumococcal disease among human immunodeficiency Virus-Infected persons: incidence, risk factors, and impact of vaccination. CID 2001; 32: 794-99.
17. Ayvazian LF, Badger TL. Disseminated lupus erythematosus ocurring among student nurses. N Engl J Med 1948; 239: 565-70.
18. Zingale SB, Sánchez Avalos JC, Andrada JA, Stringa SG, Manni JA. Appearance of anticoagulant factors and certain "autoimmune" antibodies following antigenic stimulation with blood group substances in patients with systemic lupus erythematosus. Arthritis and Rheum 1963; 6: 581-98.
19. Scofield RH, James JA. Immunization as a model for systemic lupus erythematosus. Semin Arthritis Rheum 1999; 29: 140-47.
20. Louie JS, Nies KM, Shoji KT, et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med 1978; 88: 790-92.
21. Tudela P, Martí F, Bonal J. Systemic lupus erythematosus and vaccinations against hepatitis B. Nephron 1992; 62: 236.
22. Maillefert JF, Sibila J, Toussirot E, et al. Rheumatic disorders developed after hepatitis B vaccination. Rheumatology 1999; 38: 978-83.
23. Finielz P, Lam-Kam-Sang LF, Guiserix J. Systemic Lupus Erythematosus and thrombocytopenic purpura in two members of the same family following hepatitis B vaccine. Nephrol Dial Transplant 1998; 13: 2420-21.
24. Older SA, Battafarano DF, Enzemauer RJ, Krieg AM. Can immunization precipitate connective tissue disease? Report of five cases of Systemic Lupus Erythematosus and review of the literature. Sem Arthritis Rheum 1999; 29: 131-39.
25. Abu-Shakra M, Zalmanson S, Neuman L et al. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. J. Rheumatol 2000; 27:1681.
26. Klippel JH, Karsh J, Stahl NI, et al. A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. Athritis and Rheum 1979; 22: 1321-25.
27. Lipnick R N, Karsh J, Stahl N, Blackwelder W C, Schiffman G and Klippel J. Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosupresives. The Journal of Rheumatology 1985; 12:6.
28. Williams GW, Steinberg D, Reinertsen JL, Klassen LW, Decker JL and Dolin R. Influenza immunization in systemic lupus erythematosus. A doble-blind trial. Annals of Internal Medicine 1978; 88: 729-34.
29. Recomendaciones y guías de tratamiento: Recomendaciones de Vacunas: Vacunación antineumocóccica. Disponible en: http://www.sadi.org.ar acceso 18 de Noviembre de 2002.
30. World Health Organization: WHO recommendations on pneumococcal vaccination. Infection 1989, 17: 437-41.
31. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the advisory Committee on Immunization Practices MMWR Morb Mortal Wkly Rep 1997;46 (RR-8): 1-24.
32. Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2002; 51 (RR-2):1-35.
33. Gardner P, Pichering L, Orenstein W, Gershon A, Nichol K. Guidelines for quality standards for immunizations. CID 2002; 35: 503-11.